KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Biomarin Pharmaceutical (BMRN) Accumulated Depreciation & Amortization (2016 - 2026)

Biomarin Pharmaceutical has reported Accumulated Depreciation & Amortization over the past 17 years, most recently at $16.4 million for Q1 2026.

  • For the quarter ending Q1 2026, Accumulated Depreciation & Amortization fell 25.64% year-over-year to $16.4 million, compared with a TTM value of $16.4 million through Mar 2026, down 25.64%, and an annual FY2025 reading of $79.6 million, down 17.49% over the prior year.
  • Accumulated Depreciation & Amortization came in at $16.4 million for Q1 2026, down from $79.6 million in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $104.4 million in Q4 2023 to a low of $16.4 million in Q1 2026.
  • Median Accumulated Depreciation & Amortization over the past 5 years was $53.8 million (2024), compared with a mean of $58.1 million.
  • The sharpest move saw Accumulated Depreciation & Amortization grew 3.81% in 2024, then fell 25.64% in 2026.
  • Over 5 years, Accumulated Depreciation & Amortization stood at $102.0 million in 2022, then rose by 2.37% to $104.4 million in 2023, then decreased by 7.63% to $96.4 million in 2024, then decreased by 17.49% to $79.6 million in 2025, then plummeted by 79.37% to $16.4 million in 2026.
  • Per Business Quant, the three most recent readings for BMRN's Accumulated Depreciation & Amortization are $16.4 million (Q1 2026), $79.6 million (Q4 2025), and $59.1 million (Q3 2025).